Ghafouri-Fard Soudeh, Agabalazadeh Amin, Abak Atefe, Shoorei Hamed, Hassanzadeh Taheri Mohammad Mehdi, Taheri Mohammad, Sharifi Guive
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Pharmacology, Tabriz University of Medical Sciences, Tabriz, Iran.
Front Oncol. 2021 Jun 9;11:670917. doi: 10.3389/fonc.2021.670917. eCollection 2021.
Tumors of the nervous system can be originated from several locations. They mostly have high mortality and morbidity rate. The emergence of resistance to chemotherapeutic agents is a hurdle in the treatment of patients. Long non-coding RNAs (lncRNAs) have been shown to influence the response of glioblastoma/glioma and neuroblastoma to chemotherapeutic agents. MALAT1, NEAT1, and H19 are among lncRNAs that affect the response of glioma/glioblastoma to chemotherapy. As well as that, NORAD, SNHG7, and SNHG16 have been shown to be involved in conferring this phenotype in neuroblastoma. Prior identification of expression amounts of certain lncRNAs would help in the better design of therapeutic regimens. In the current manuscript, we summarize the impact of lncRNAs on chemoresistance in glioma/glioblastoma and neuroblastoma.
神经系统肿瘤可起源于多个部位。它们大多具有较高的死亡率和发病率。化疗药物耐药性的出现是治疗患者的一个障碍。长链非编码RNA（lncRNA）已被证明会影响胶质母细胞瘤/胶质瘤和神经母细胞瘤对化疗药物的反应。MALAT1、NEAT1和H19是影响胶质瘤/胶质母细胞瘤对化疗反应的lncRNA。除此之外，NORAD、SNHG7和SNHG16已被证明参与赋予神经母细胞瘤这种表型。预先确定某些lncRNA的表达量将有助于更好地设计治疗方案。在本手稿中，我们总结了lncRNA对胶质瘤/胶质母细胞瘤和神经母细胞瘤化疗耐药性的影响。
